Can an Emerging PET Radiotracer Be a Viable Alternative to Multiparametric MRI for Detecting Prostate Cancer Recurrence?
In an analysis of patients with intraprostatic/prostate bed findings of biochemical prostate cancer recurrence, the use of 18F-DCFPyL PET/CT led to an 82.3 percent cancer detection rate in comparison to 80 percent for multiparametric MRI, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
For patients with intraprostatic/prostate bed findings of biochemical prostate cancer recurrence, the use of 18F-DCFPyL PET/CT with positron emission tomography/computed tomography (PET/CT) offers comparable detection to multiparametric magnetic resonance imaging (mpMRI), according to researchers from the National Cancer Institute, who presented their findings at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
For the prospective study, researchers reviewed data from 213 patients (mean age of 67) with biochemical recurrence of prostate cancer. All patients in the study cohort had mpMRI and PET/CT with 18F-DCFPyL (Pylarify, Progenics Pharmaceuticals/Lantheus). The study authors noted that 115 patients had positive intraprostatic/prostate bed findings. These patients included 58 post-prostatectomy patients and 57 patients who were previously treated with radiation, according to the study.
For the 53 prostate cancer lesions diagnosed in post-prostatectomy patients, 22 lesions were detected with MRI alone, six lesions were diagnosed with PSMA PET/CT alone and 25 lesions were detected with a combination of the two modalities. For this cohort, researchers noted cancer detection rates of 83.7 percent for mpMRI, 92.1 percent for PSMA PET/CT and 94.2 percent for the combination of the two modalities.
In the above images, the use of 18F-DCFPyL PET/CT reveals several abnormal foci while multiparametric MRI was negative in a 70-year-old patient who had biochemical recurrence nine years after previous treatment for prostate cancer. (Images courtesy of the Society for Nuclear Medicine and Molecular Imaging (SNMMI)).
For the 66 prostate cancer lesions detected in post-radiation patients, 17 lesions were diagnosed with MRI alone, six lesions were detected by PSMA PET/CT alone and 43 lesions were diagnosed with a combination of the two modalities. The study authors noted cancer detection rates of 83.7 percent for mpMRI, 92.1 percent for PSMA PET/CT and 94.2 percent for the modality combination in this cohort.
“18F-DCFPyL-PET/CT and mpMRI show similar cancer detection rates of intraprostatic/prostate bed recurrences, and the combination of 18F-DCFPyL-PET/CT and mpMRI provides superior diagnostic performance than either modality alone,” wrote study co-author Baris Turkbey, M.D., a senior clinician and radiologist affiliated with the Molecular Imaging Branch of the National Cancer Institute and National Institutes of Health (NIH) in Bethesda, Md., and colleagues.
While mpMRI demonstrated a higher detection rate than PSMA PET/CT for prostate cancer lesions, the study authors noted a lack of pathology confirmation for all lesions and a higher number of false positives with mpMRI.
Reference
1. Mena E, Lindenberg L, Lin F, et al. Comparison between 18F-DCFPyL-PET/CT and multiparametric MRI in assessing recurrence within the prostate in patients with biochemical recurrence of prostate cancer. Poster abstract presented at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting June 24-27, 2023 in Chicago. Available at https://am.snmmi.org/iMIS/SNMMI-AM . Accessed August 16, 2023.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
